Loading...
The evolving landscape of predictive biomarkers of response to PARP inhibitors
Poly(ADP-ribose) polymerase inhibitors (PARPis) are DNA-damaging agents that trap PARP-DNA complexes and interfere with DNA replication. Three PARPis — olaparib, niraparib, and rucaparib — were recently approved by the FDA for the treatment of breast and ovarian cancers. These PARPis, along with 2 o...
Saved in:
| Published in: | J Clin Invest |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Clinical Investigation
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5919798/ https://ncbi.nlm.nih.gov/pubmed/29664016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI120388 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|